Company intelligence / Profile preview

University spin-out in stealth mode

Ownership: Private
Development stage: Preclinical

Overview

Lead therapy TGM-010 has shown promise in animal models of multiple sclerosis and ALS, reducing neurological disability and preserving neuron function

Therapeutic areas: Neurology
Modalities: Antibody therapiesNeuroprotective antibodies
Industry: Biotech

Beyond the preview

Go deeper on University spin-out in stealth mode.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on University spin-out in stealth mode.

Explore the full profile